The Latest
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit Of ORPATHYS® Plus TAGRISSO® In Treatment-Naïve Patients With MET-Overexpressing EGFR-mutated Lung Cancer In China
HUTCHMED announces that its SANOVO trial shows notable progression-free survival benefits with ORPATHYS® plus TAGRISSO® in EGFR-mutated lung cancer patients in China.